Supplementary Information for

Evolution Inspired Engineering of Megasynthetases

Kenan A. J. Bozhüyük^{1,2,3,&,*}, Leonard Präve^{1,3,&}, Carsten Kegler^{1,&}, Sebastian Kaiser^{1,4}, Yan-Ni Shi³, Wolfgang Kuttenlochner⁵, Leonie Schenk^{1,3}, T.M. Mohiuddin³, Michael Groll⁵, Georg K. A. Hochberg^{4,6,7}, Helge B. Bode^{1,3,6,7,8,*}

¹Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions, 35043 Marburg, Germany

²Myria Biosciences AG, Basel, Switzerland

³Molecular Biotechnology, Department of Biosciences, Goethe-University Frankfurt, 60438 Frankfurt, Germany

⁴Evolutionary Biochemistry Group, Max-Planck-Institute for Terrestrial Microbiology, 35043 Marburg, Germany

⁵Chair of Biochemistry, Center for Protein Assemblies, Technical University of Munich, Ernst-Otto-Fischer-Straße 8, 85748 Garching, Germany

⁶Center for Synthetic Microbiology (SYNMIKRO), Phillips University Marburg, 35043 Marburg, Germany

⁷Department of Chemistry, Phillips University Marburg, 35043 Marburg, Germany

⁸Senckenberg Gesellschaft für Naturforschung, 60325 Frankfurt, Germany

[&]These authors contributed equally to this work

*Correspondence authors: Kenan.Bozhueyuek@mpi-marburg.mpg.de, helge.bode@mpi-marburg.mpg.de

1. Material and Methods

1.1. Cultivation of strains

All *E. coli* DH10B::*mtaA* cells were cultured either on liquid or solid low salt LB medium ((pH 7.5, 10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl). Either kanamycin (50 μ g/ml), chloramphenicol (34 μ g/ml) or spectinomycin (50 μ g/ml) were added as selection markers. Solid media contained 1% (w/v) agar. Cells were cultivated at 37 °C and at 22 °C for peptide production cultures.

1.2. Cloning of biosynthetic gene clusters and NRPS modules

For use as template, genomic DNA (gDNA) was extracted from bacteria indicated in Table S1 by use of the Gentra Puregene Yeast/Bact. Kit (Qiagen) and the Monarch® Genomic DNA Purification Kit (NEB) which in turn was taken as template for the PCR amplification. The proof-reading PCR polymerase Q5® High-Fidelity DNA Polymerase (NEB) and *Phusion* DNA Polymerase (NEB/Thermo Fisher Scientific) in their standard and hot start variations were employed. Oligonucleotides for the PCR and the correct product size are documented in Table S4. In specified cases (Table S4) already cloned NRPS parts were used as template for the PCR. PCR products were agarose gel purified taking the Monarch® DNA Gel Extraction Kit (NEB) to be used as substrate for the Gibson cloning procedure using the Gibson Assembly® Master Mix or the NEBuilder® HiFi DNA Assembly Cloning Kit (NEB). In cases indicated in Table S4 restriction enzyme digests with enzymes indicated were used as one part of the substrate for the Gibson cloning step.

The vector pCK_0407 was cloned in a classic fashion. To this end the plasmid pCK_0407 was linearised using the restriction enzymes AvrII/Xbal and the 1.750 bp fragment ligated to the 1.933 bp fragment of the AvrII/Xbal digest of pCDFDuet (Merck-Novagen).

1.3. Heterologous expression of NRPS constructs and HPLC-MS analysis

After plasmid transformation into *E. coli* DH10B::*mtaA*, cells were grown overnight in LB medium containing all necessary antibiotics (50 µg/ml kanamycin, 34 µg/ml chloramphenicol, 100 µg/ml spectinomycin). 10 ml LB medium containing antibiotics, 0.002 mg/ml L-arabinose and 2 % (v/v) XAD-16 were inoculated with 1 % overnight grown culture. After incubation for 72 h at 22 °C, XAD-16 beads were harvested and one culture volume methanol was added. Methanol extraction was conducted for 60 min at 22 °C. The organic phase was filtrated and diluted 1:10 in methanol. Cleared HPLC-UV-MS analysis was conducted on an UltiMate 3000 system (Thermo Fisher) coupled to an AmaZonX mass spectrometer (Bruker) with an ACQUITY UPLC BEH C18 column

(130 Å, 2.1 mm × 100 mm, 1.7-µm particle size, Waters) at a flow rate of 0.4 ml min-1 (5–95% acetonitrile/water with 0.1% formic acid, vol/vol, 16 min, UV detection wavelength 190–800 nm). HPLC-UV-HRMS analysis was conducted on an UltiMate 3000 system (Thermo Fisher) coupled to an Impact II qTof mass spectrometer (Bruker) with an ACQUITY UPLC BEH C18 column (130 Å, 2.1 mm × 100 mm, 1.7-µm particle size, Waters) at a flow rate of 0.4 ml min-1 16 min, UV detection wavelength 190–800 nm). Evaluation was performed using DataAnalysis 5.3 software (Bruker).

For peptide quantification of NRPS-8- to -20 the production medium was, deviating from above, XPP medium¹ without phenylalanine with 1 mM ß-alanine added.

1.4. Peptide Purification

Compounds **4**, **5**, **7**, **10**, **26**, **41** and **61** were produced in *E. coli* DH10B::*mtaA* expressing the respective NRPS variants. 4L XPP medium containing 34 µg/ml chloramphenicol, 0.002 % L-arabinose and 2 % XAD 16N beads was inoculated with 1 % overnight grown culture as described in section S1.3. The culture was incubated at 180 rpm for 72 h at 22 °C. Subsequently, the XAD 16N beads were extracted 3 times with 500 ml methanol for 30 minutes, stirring. Solvent was fully removed at reduced pressure and the crude extract was completely solved in DMSO in order to purify it by preparative HPLC–MS (LC-MS-System 1260 Infinity II Preparative LC/MSD from Agilent). A C3 column (Agilent ZORBAX 300XB-C3) utilizing a gradient of 40-55 % ACN/H2O (+0.1 % formic acid) was used. The compound was freeze-dried and the purity of the compound was determined by NMR and HPLC-HR-MS.

1.5. Peptide quantification

The absolute production titres were calculated as previously described². Therefore, calibration curves based on pure **1** (for quantification of **1**, **2** and **3**), **4** (**4**, **5**, **15**, **17**, **18**, **32** and **33**), **10** (**6**, **7**, **8**, **9**, **10**, **11** and **16**), **26** (**26**, **27**, **28**, **29**), **34** (**34** and **35**), **36** (**36** and **37**), **38** (**38** and **39**), and **41** (**40**, **41** and **42**), were prepared. The pure compounds were prepared at different concentrations: **1** utilizing a standard curve with concentrations of 5000, 500, 50, 5 and 0.5 μ g L⁻¹; **4** utilizing a standard curve with concentrations of 10, 4, 1, 0.4, 0.1, 0.04 and 0.01 mg l⁻¹, **10** utilizing a standard curve with concentrations of 10, 4, 1, 0.4, 0.1 and 0.04 mg l⁻¹, **26** utilizing a standard curve with concentrations of 10, 4, 1, 0.4, 0.1 and 0.04 mg l⁻¹, **26** utilizing a standard curve with concentrations of 10, 4, 1, 0.4, 0.1 and 0.04 mg l⁻¹, **26** utilizing a standard curve with concentrations of 10, 4, 0.004 and 0.004 mg l⁻¹, **34**, **36** and **38** utilizing a standard curve with concentrations of 100, 20, 4, 0.8 and 0.16 mg l⁻¹, **41** utilizing a standard curve with concentrations of 100, 20, 4, 0.8 and 0.1562 mg l⁻¹ and measured by LC-MS using HPLC/MS measurements as described above. To ensure sample signals being within the range

of the standard curve they were diluted when necessary. The peak area for each compound at different concentrations was calculated using Compass Data Analysis and used for the calculation of a standard curve passing through the zero point. Triplicates of all *in vivo* experiments were measured. The pure peptide standards **1**, **34**, **36**, **38** were synthesized in-house, **4**, **10**, **26** and **41** were purified from production cultures.

1.6. Chemical Synthesis

The linear peptide **1** was synthesized on preloaded resin (0.25 mmol H-Leu-2CITrt PS resin, Sigma Aldrich, Germany) by solid phase peptide synthesis using standard Fmoc/t-Bu chemistry. Fmoc protected amino acids or fatty acids were activated by mixture of 5 eq. Fmoc-AA-OH (or fatty acid), 12 eq. N,N-diisopropylethylamine (DIPEA, Iris Biotech, c = 2.4 M), 5 eq. O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, Carbolution Chemicals) in 15 ml dimethylformamide (DMF, Carl Roth, Germany). The resin was incubated with the activated amino acid/fatty acid mixture for 2 h at room temperature. After each coupling, the resin was washed with NMP (5 ×), DMF (5 ×) and DCM (5 ×). Finally, the peptide was cleaved by addition of 20 ml of a mixture of Hexafluoroisopropanol (HFIP) and DCM (1:4 v/v). Subsequently, the peptide was deprotected upon addition of 2 ml Trifluoroacetic acid (TFA) incubating for 2 h at room temperature. The linear peptide was dissolved in MeOH in order to purify it by semi-preparative HPLC–MS (Agilent LC-MS-System 1260 Infinity II Analytical-Scale LC/MSD) utilizing a C18 column (Eclipse XDB-C18 (9.4 x 250 mm, 5 µm). The purity was determined by NMR and HPLC-HR-MS analysis.

Chemical synthesis of peptides **34**, **36**, **38** was performed as described previously². The linear sequences were synthesized on preloaded resins (H-AA-2CITrt PS resin, Sigma Aldrich, Germany) on a 25 μ M scale with a Syro Wave peptide synthesizer (Biotage, Sweden) by using standard Fmoc/*t*-Bu chemistry. Fmoc-amino acids were purchased from Carbolution Chemicals (Germany), Iris Biotech (Germany) or Bachem (Switzerland). Therefore, the resin was placed in a plastic reactor vessel with a Teflon frit and an amount of 6 eq. of amino acid derivative (c = 0.2 M) was activated *in situ* at room temperature with 6 eq. of *O*-(6-chlorobenzotriazol-1-yl)-*N*,*N*,*N'*-tetramethyluronium hexafluorophosphate (HCTU, Carl Roth, Germany, c = 0.6 M) in dimethylformamide (DMF, Carl Roth, Germany) in the presence of 12 eq. *N*,*N*-diisopropylethylamine (DIPEA, Iris Biotech, c = 2.4 M) in *N*-methylpyrrolidone (NMP, Iris Biotech) for 50 min. Fmoc-protecting groups were removed with a solution of 40 % piperidine (Iris Biotech) in NMP (v/v %) for 5 min and followed by a second deprotection step with 20 % piperidine in NMP (v/v %) for 10 min. After each coupling and deprotection step, the resin was washed with NMP (4

×). After addition of the final amino acid and deprotection step, the resin was washed with NMP (5 ×), DMF (5 ×) and DCM (5 ×).

For total deprotection or cleavage 0.5 mL 95 % trifluoroacetic acid (TFA, Iris Biotech) and 2.5 % triisopropylsilane (TIS, Sigma Aldrich) in water were added to peptidyl resin and the mixture was agitated for at least 1 h at room temperature. The resin was removed by filtration and washed twice with TFA. Then the cleavage cocktail was evaporated. Linear peptide was dissolved in MeOH in order to purify it by semi-preparative HPLC–MS (Agilent LC-MS-System 1260 Infinity II Analytical-Scale LC/MSD) utilizing a C18 column (Eclipse XDB-C18 (9.4 x 250 mm, 5 µm). The purity was determined by HPLC-HR-MS and NMR.

1.7. Expression and purification of yeast 20 S proteasome

The yeast 20S proteasome was prepared as previously described^{3,4}.

1.8. IC₅₀ value determination with purified yCP

Concentration of purified yeast 20 S proteasome (yCP) was determined spectrophotometrically at 280 nm. yCP (final concentration: 0.05 mg/mL in 100 mM Tris-HCI, pH 7.5) was mixed with DMSO as a control or serial dilutions of fellutamide derivatives in DMSO, thereby not surpassing a final concentration of 10% (v/v) DMSO. After an incubation time of 45 min at RT, fluorogenic substrates Boc-Leu-Arg-Arg-AMC, Z-Leu-Leu-Glu-AMC and Suc-Leu-Leu-Val-Tyr-AMC (final concentration of 200 μ M) were added to measure the residual activity of caspase-like (C-L, β 1 subunit), trypsin-like (T-L, β 2 subunit) and chymotrypsin-like (ChT-L, β 5 subunit), respectively. The assay mixture was incubated for another 60 min at RT and afterwards diluted 1:10 in 20 mM Tris-HCl, pH 7.5. The AMC-molecules released by hydrolysis were measured in triplicate with a Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies) at λ_{exc} =360 nm and λ_{em} =460 nm. Relative fluorescence units were normalized to the DMSO treated control. The calculated residual activities were plotted against the logarithm of the applied inhibitor concentration and fitted with GraphPad Prism 5. Half maximum inhibitory concentration (IC₅₀) values were deduced from the fitted data. They depend on enzyme concentration and are comparable within the same experimental settings.

1.9. Crystallisation and structure determination of the yeast 20S proteasome core particle (yCP) in complex with 41.

Crystals of yCP were grown in hanging drops at 20°C as previously described^{3,4}. The protein concentration used for crystallization was 40 mg/mL in Tris / HCl (20 mM, pH 7.5) and EDTA (1

mM). The drops contained 1 µL of protein and 1 µL of the reservoir solution [30 mM magnesium acetate, 100 mM 2-(N-morpholino)ethanesulfonic acid (pH 6.8) and 10% (wt/vol) 2-methyl-2,4-pentanediol]. Crystals appeared after two days and were incubated with a fellutamide derivative at final concentrations of 10 mM for at least 24 h. Droplets were then complemented with a cryoprotecting buffer [30% (wt/vol) 2-methyl-2,4-pentanediol, 15 mM magnesium acetate, 100 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.9] and vitrified in liquid nitrogen. The dataset from the yCP: **41** complex was collected using synchrotron radiation ($\lambda = 1.0$ Å) at the X06SA-beamline (Swiss Light Source, Villingen, Switzerland). X-ray intensities and data reduction were evaluated using the XDS program package (Table Sx)⁵. Conventional crystallographic rigid body, positional, and temperature factor refinements were carried out with REFMAC5⁶ using coordinates of the yCP structure as starting model (PDB ID 5CZ4)⁷. For model building, the programs SYBYL and COOT⁸ were used. The final coordinates yielded excellent R factors, as well as geometric bond and angle values. Coordinates were confirmed to fulfill the Ramachandran plot and have been deposited in the RCSB (PDB ID 8BW1)

1.10 Evolutionary analysis of ATC tridomains (XUs) from NRPS using PhyML_Multi

The amino acid sequence of NRPS were collected from our *Photorhabdus* and *Xenorhabdus* genome collection. We also included a few NRPS representatives from actinomycetes, cyanobacteria and other proteobacteria in our analysis (sup. x). XUs from NRPS protein sequences were extracted from our NRPS dataset using local BLAST with the second XU from GxpS of Photorhabdus laumondii TT01 as query. XUs were aligned using MUSCLE v3.8.31⁹ and trimed with trimAl v1.2¹⁰. This alignment was used for the evolutionary analysis using the software PhyML_Multi. We specified that PhyML_multi search for two trees under a hidden markov model that together best fit the alignment. Since PhyML_Multi does not have a model finder, the model finder of IQ-tree¹⁰ with the selection of '-msub nuclear' was used. IQ-tree chose JTT¹¹ as the best fit model which was also used for the analysis with PhyML_Multi with a 4-category gamma distribution of among site rate-variation. Afterwards, the log likelihood of tree 1 was deducted from the log likelihood of tree 2 and plotted.

1.11 Evolutionary analysis of the T domain from NRPS using PhyML_Multi

The T domain dataset covered the amino acid sequence of the A-T-Linker and the T domain. This area was extracted from our NRPS dataset using local BLAST with the third T domain from GxpS of Photorhabdus laumondii TT01 as query. The T domains were aligned using MUSCLE and

carefully trimmed manually to reduce gaps. Afterwards, the software PhyML_Multi was used to detect recombination breakpoints and phylogenetic histories within the T domain.

1.12 Topological comparison of different phylogenetic trees

The four different trees generated by PhyML_Multi were pruned using the software mesquite¹² to reduce the number branches on the trees for visual clarity. Trees were compared using the R package phytools¹³.

Strain	Genotype/NRPS	Reference
<i>E. coli</i> DH10B	F_mcrA (<i>mrr-hsd</i> RMS- <i>mcr</i> BC),	14
	80 <i>lac</i> ΖΔ, M15, Δ <i>lac</i> X74 <i>rec</i> A1	
	endA1 araD 139∆(ara, leu)7697	
	galU galK λ rpsL (Strr) nupG / -	
<i>E. coli</i> DH10B:: <i>mta</i> A	DH10B with <i>mtaA</i> from	15
	pCK_ <i>mtaA</i> ∆entD / -	
<i>Bacillus subtilis</i> subsp. subtilis str. 168 DSM 402	WT (srfAB, ppsA)	DSMZ
M. xanthus DK1622	WT (MchABC)	16, 17
Pseudomonas lurida sp.	WT (viscA)	18
MYb11		10
Serratia sp. SCBI	WT (<i>swrA</i>)	19
S. marcescens DSM 12481	WT (<i>swrW</i>)	DSMZ
P. luminescens subsp.	WT (gxpS, kolS)	DSMZ
laumondii TT01		
P. temperata KT122	WT (4325)	20
X. bovienii SS-2004	WT (<i>txIA</i>)	21
X. doucetiae DSM 17909	WT (xabA, prtA)	DMSZ
X. indica DSM17382	WT (<i>xldS</i> , <i>xtvB</i> , <i>xeyS</i> ,	DSMZ
	XINDV2_09420)	
X. innexi DSM 16336	WT (fitAB*1)	DSMZ
X. mauleonii DSM 17908	WT (<i>ftrAB</i> * ²)	DSMZ
X. miraniensis DSM 17902	WT (ambS)	DMSZ
X. nematophila ATCC19061	WT (<i>xtpS</i> , <i>PAX</i>)	ATCC
X. stockiae DSM 17904	WT (xabA)	DMSZ
X. szentirmaii DSM 16338	WT (xabA)	DMSZ
Xenorhabdus sp. KK7.4	WT (XEKKV2_12060)	21,22
Chondromyces crocatus Cm c5 DSM 14714	WT (cpnD)	DMSZ

Table S1. Strains used in this work.

NRPS-	GenPept	GenBank	locus tag	gene
construct	locus/protein ID			
NRPS-8	PHM30481.1	NIBU01000054.1	Xinn_03284	fitAB
	PHM29999	NIBU01000077.1	Xinn_03635	
NRPS-9	YP_003466710.1	FN667741	XBJ1_0775	txIA
NRPS-10	WP_148886166.1	NZ_VNHN01000062.1	LY16_RS14705	prtA
NRPS-11	WP_099121989.1	NZ_NJAH01000014.1	Xekk_RS12280	XEKKV2_
				12060
NRPS-12	MBC8943736.1	NKHP01000001.1	Xind_00118	XINDV2_0
				9420
NRPS-13	AIM23801.1	CP003424.1	SERRSCBI_21215	swrA
NRPS-14	WP_187681863	NZ_JACSZU01000009.1	IAI52_RS13305	viscA
NRPS-15	WP_012987679	NC_013892.1	XBJ1_1126	xfpS
NRPS-16	CAB13717.2	AL009126.3	BSU18340	ppsA
NRPS-19	PHM39367.1	NITY01000011.1	Xmau_02974	ftrAB
	PHM39368		Xmau_02975	
NRPS-20	BAD60917.1	AB193098.2	AB193098.2	swrW
NRPS-17	ABF89060.1	CP000113.1	MXAN_4077	mchAB
	ABF89457.1		MXAN_4078	
NRPS-18	PHM40846.1	NIUA01000001.1	Xszus 00521	xabA

Table S2. Protein and nucleic acid references to data bank used for NRPS-constructs.

NRPS	Plasmids	Genotype	Reference
	pCOLA_ara/	ori ColA, kanR, araC- P _{BAD} , and tacl	23
	tacl		04
	pCK_0401	ori p15A, cmR, araC- P _{BAD} , and tacl	24
	pCK_0407	ori ColDF13, specR, <i>araC- P_{BAD}</i> , and tacl; mtaA	This work
-1	pLP23	ori ColA, <i>kan^k, araC- P_{BAD,} xabABC</i> _C1A1- <i>gxpS</i> _T3C/E4A4T4C/E5A5T5TE and <i>tacl</i>	This work
-2	pLP24	ori ColA, <i>kan^R</i> , <i>araC- P_{BAD}</i> , <i>xabABC</i> _C1A1T1 _{1/2} - <i>gxpS</i> _T3 _{1/2} C/E4A4T4C/E5A5T5TE and <i>tacl</i>	This work
-3	pFP7	ori ColA, <i>kan^R</i> , <i>araC- P_{BAD}</i> , <i>xabABC</i> _C1A1T1 _{1/2} - <i>axpS</i> T3 _{1/2} C/E4A4T4C/E5A5T5TE and <i>tacl</i>	This work
-4	pFP8	ori ColA, kan ^R , araC- P _{BAD} , xabABC_C1A1T1 _{1/2} - gxpS_T3 _{1/2} C/E4A4T4C/E5A5T5TE and tacl	This work
-5	pFP9	ori ColA, kan ^R , araC- P _{BAD} , xabABC_C1A1T1 _{1/2} - gxpS_T3 _{1/2} C/E4A4T4C/E5A5T5TE and tacl	This work
-6	pFP11	ori ColA, kan ^R , araC- P _{BAD} , xabABC_C1A1T1 _{1/2} - gxpS_T3 _{1/2} C/E4A4T4C/E5A5T5TE and tacl	This work
-7	pLP31	ori ColA, kan ^R , araC- P _{BAD} , xabABC_C1A1T1- axpS C/E4A4T4C/E5A5T5TE and tacl	This work
-8	pCK_0683	ori p15A, cmR, <i>araC- P_{BAD}, fitAB</i> 6 modular NRPS <i>X. mauleonii</i>	This work
-9a	pCK_0760	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>txlA</i> C1A1 – T1 modules 2-6 <i>fitAB</i>	This work
-9b	pCK_0761	ori p15A, cmR, <i>araC- P_{BAD}, txIA</i> C1A1 T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-10a	pCK_0762	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>prtA</i> C1A1 – T1 modules 2-6 <i>fitAB</i>	This work
-10b	pCK_0762	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>prtA</i> C1A1 T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-11a	pCK_0768	ori p15A, cmR, <i>araC- P_{BAD}, xucA*</i> C1A1 ^{Val} – T1 modules 2-6 <i>fitAB</i>	This work
-11b	pCK_0768	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>xucA*</i> C1A1 ^{Val} T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-12a	pCK_0820	ori p15A, cmR, <i>araC- P_{BAD}, xucA*</i> C1A1 ^{Ser} – T1 modules 2-6 <i>fitAB</i>	This work
-13a	pCK_0822	ori p15A, cmR, <i>araC- P_{BAD}, xucA</i> * C1A1 ^{Leu} – T1 modules 2-6 <i>fitAB</i>	This work
-13b	pCK_0823	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>viscA</i> C1A1 ^{Leu} T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-14a	pCK_0824	ori p15A, cmR, <i>araC- P_{BAD}, xucA</i> * C1A1 ^{Leu} – T1 modules 2-6 <i>fitAB</i>	This work
-14b	pCK_0825	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>xucA*</i> C1A1 ^{Leu} T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-15a	pCK_0826	ori p15A, cmR, <i>araC- P_{BAD}, xtpS</i> C1A1 ^{Leu} – T1 modules 2-6 <i>fitAB</i>	This work
-15b	pCK_0827	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>xtpS</i> C1A1 ^{Leu} T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-16a	pCK_0828	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>xtpS</i> C1A1 ^{Leu} T1 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-19	pCK_0680	ori p15A, cmR, <i>araC- P_{BAD}, ftrAB</i> 6 modular WT NRPS	This work
-17a	pCK_0868	ori CloDF13, specR, araC-P _{BAD} mchA-PKS and tacl	This work

 Table S3. Plasmids and corresponding NRPSs used in this work.

-20b	pCK_0870	ori p15A, cmR, <i>araC- P_{BAD}</i> , <i>swrW</i> C1A1 ^{Ser} modules 2-6 <i>ftrAB</i>	This work
-19a	pCK_0873	ori p15A, cmR, <i>araC- P_{BAD}</i> , (<i>mchA-</i> PKS <i>mchB</i> C1A1MT ^{Thr} - modules 2-6 <i>fitAB</i>	This work
-20b	pSB002	ori p15A, cmR, <i>araC- P_{BAD}, xabA</i> C1A1 ^{Pro} T1_C2A2 ^{Giy} T2 _{1/2} – modules 2-6 <i>fitAB</i>	This work
-21a	pLS_019	ori p15A, cm ^R , araC-P _{BAD} I-CeuI, I-SceI gxps_A ₁ T ₁ C/E ₂ A ₂ _xabA_T ₃ C ₄ A ₄ _gxps_T ₄ C/E ₅ A ₅ T ₅ TE and <i>tacI-araE</i>	This work
-21b	pLS_191	ori p15A, cm ^R , araC-P _{BAD} I-Ceul, I-Scel gxps_A ₁ T ₁ C/E ₂ A ₂ T ₂ ^{1/2} _xabA_T3 ^{1/2} C ₄ A ₄ T ₄ ^{1/2} _gxps_T4 ^{1/2} C/E ₅ A ₅ T ₅ TE and <i>tacl-araE</i>	This work
-22a	pLS_018	ori p15A, cm ^R , araC-P _{BAD} I-CeuI, I-SceI gxps_A ₁ T ₁ C/E ₂ A ₂ _ <i>xlds</i> _T ₂ C ₃ A ₃ _ <i>gxps</i> _T ₄ C/E ₅ A ₅ T ₅ TE and <i>tacI-araE</i>	This work
-22b	pLS_017	ori p15A, cm ^R , araC-P _{BAD} I-Ceul, I-Scel gxps_A ₁ T ₁ C/E ₂ A ₂ T ₂ ^{1/2} _ <i>xlds</i> _T ₂ ^{1/2} C ₃ A ₃ T ₃ ^{1/2} _ <i>gxps</i> _T ₄ ^{1/2} C/ $E_5A_5T_5TE$ and <i>tacl-araE</i>	This work
-23a	pLS_009	ori p15A, cm ^R , araC-P _{BAD} I-Ceul, I-Scel gxps_A ₁ T ₁ C/E ₂ A ₂ _ <i>cpnd</i> _T ₂ C ₃ A ₃ _ <i>gxps</i> _T ₄ C/E ₅ A ₅ T ₅ TE and <i>tacl-araE</i>	This work
-23b	pLS_008	ori p15A, cm ^R , araC-P _{BAD} I-Ceul, I-Scel gxps_A ₁ T ₁ C/E ₂ A ₂ T2 ^{1/2} _cpnd_T ₂ ^{1/2} C ₃ A ₃ T ₃ ^{1/2} _gxps_T ₄ ^{1/2} C/E ₅ A ₅ T ₅ TE and <i>tacl-araE</i>	This work
-24a	pLS_003	ori p15A, cm ^R , araC-P _{BAD} I-CeuI, I-SceI gxps_A ₁ T ₁ C/E ₂ A ₂ _mchC _A _T ₂ C ₃ A ₃ _gxps_T ₄ C/E ₅ A ₅ T ₅ TE and <i>tacI-araE</i>	This work
-24b	pLS_002	ori p15A, cm ^R , araC-P _{BAD} I-Ceul, I-Scel gxps_A ₁ T ₁ C/E ₂ A ₂ T2 ^{1/2} $mchC_A_T2^{1/2}C_3A_3T_3^{1/2}$ $gxps_T4^{1/2}$ $^2C/E_5A_5T_5TE$ and $tacl-araE$	This work
-25	pPI16_XUT	ori p15A, <i>cm</i> ^R , <i>ara</i> C- <i>P</i> _{BAD} <i>xld</i> S_C1A1T1 _{1/2} - <i>xab</i> A_T1 _{1/2} C1- <i>kol</i> S_A2T2C3- <i>gxp</i> S_A2T2 _{1/2} - <i>xtv</i> AB_T2 _{1/2} Red <i>tacl</i> and <i>araE</i>	This work
-26	pPI16	ori p15A, <i>cm</i> ^R , <i>ara</i> C- <i>P</i> _{BAD} <i>xld</i> S_C1A1T1 _{1/2} - <i>xab</i> A_T1 _{1/2} C1- <i>kol</i> S_A2T2C3- <i>gxp</i> S_A2T2 _{1/2} - <i>xtv</i> AB_T2 _{1/2} Red <i>tacl</i> and <i>araE</i>	This work
-27	pPI16_typeII	ori p15A, <i>cm</i> ^R , <i>araC-P_{BAD} xldS</i> _C1A1T1 _{1/2} - <i>xabA</i> _T1 _{1/2} C1- <i>kolS</i> _A2T2C3- <i>gxpS</i> _A2T2 _{1/2} - <i>xtvAB</i> _T2 _{1/2} Red <i>tacl</i> and <i>araE</i>	This work
-28	pPI16_end	ori p15A, <i>cm</i> ^R , <i>ara</i> C- <i>P</i> _{BAD} <i>xld</i> S_C1A1T1 _{1/2} - <i>xab</i> A_T1 _{1/2} C1- <i>kol</i> S_A2T2C3- <i>gxp</i> S_A2T2 _{1/2} - <i>xtv</i> AB T2 _{1/2} Red <i>tacl</i> and <i>araE</i>	This work

Table S4. Primer and templates used in this work to generate indicated plasmids. Sizes of the PCR products are depicted below the template.

Plasmids	Oligo-	Sequence (5' to 3'), alternatively restriction	Template
	nucleotides	enzymes	Product size in bp
pLP23	LP134	TGGGCTAACAGGAGGAATTCCATGCCTATGTCG	X. stockiae gDNA
		TGCAATCG	3.062
	LP135	GCTTGGTACTCATGCGTGACTACCGC	
	LP132	CAATCTGCGGTAGTCACGCATGAGTACCAAGC	pJW76
		GCCACAAGGGGAAATTG	5.347
	LP133	GAACATTCGGATCAAGTACCGTTAACGCGG	
	LP136	AACGGTACTTGATCCGAATGTTC	pJW76
	LP137	GGAATTCCTCCTGTTAGCCC	5.545
pLP24	LP134	TGGGCTAACAGGAGGAATTCCATGCCTATGTCG	X. stockiae gDNA
		TGCAATCG	3.148
	LP139	AGAAACTGTCATGTCGGCCAACCTGTTCTAATC	
		CTAATAAACTTTGC	
	LP138	GTTGGCCGACATGACAGTTTCTTTGCC	pJW76
	LP133	GAACATTCGGATCAAGTACCGTTAACGCGG	5.251
	LP136	AACGGTACTTGATCCGAATGTTC	pJW76
	LP137	GGAATTCCTCCTGTTAGCCC	5.545
pFP7	LP55	GAGGAATTCCATGCCTATGTCGTGCAATCG	X. stockiae gDNA
•	LP60	CGCCCAAGGCAAAGAAATGGTCACGGCGACCA	3.149
		ACCTG	
	LP59	CCATTTCTTTGCCTTGGGCGGTCAC	pJW76
	LP44	GTAAATCACATACGCCAGATGTCGTGAGGTC	5.308
	LP43	CGACATCTGGCGTATGTGATTTACACTTCTG	pJW76
	LP56	CGACATAGGCATGGAATTCCTCCTGTTAGC	5.487
pFP8	LP55	GAGGAATTCCATGCCTATGTCGTGCAATCG	X. stockiae gDNA
•	LP62	CGAGTGACCGCCCAATTCAAAGAAATGGTCAC	3.157
	LP61	TTGAATTGGGCGGTCACTCGCTGTTGGC	pJW76
	LP44	GTAAATCACATACGCCAGATGTCGTGAGGTC	5.300
	LP43	CGACATCTGGCGTATGTGATTTACACTTCTG	pJW76
	LP56	CGACATAGGCATGGAATTCCTCCTGTTAGC	5.487
pFP9	LP55	GAGGAATTCCATGCCTATGTCGTGCAATCG	X. stockiae gDNA
1 ²	LP64	CTGACTGCCAGAAGAGAGTCACCACCC	3.171
	LP63	GACTCTCTTCTGGCAGTCAGGATGATCGAACG	pJW76
	1 P44	GTAAATCACATACGCCAGATGTCGTGAGGTC	5.286
	L P43	CGACATCTGGCGTATGTGATTTACACTTCTG	nJW76
	LP56	CGACATAGGCATGGAATTCCTCCTGTTAGC	5.487
pFP11	L P55	GAGGAATTCCATGCCTATGTCGTGCAATCG	X stockiae gDNA
P	L P66	CAATCCTATACGACGTATACGGGCAGTCATCTG	3.202
	L P65	CCGTATACGTCGTATAGGATTGGGCCTGTC	n.IW76
		GTAAATCACATACGCCAGATGTCGTGAGGTC	5 257
	1 P43	CGACATCTGGCGTATGTGATTTACACTTCTG	n IW/76
	L P56	CGACATAGGCATGGAATTCCTCCTGTTAGC	5 487
nl D31	LI 30		X stockiae gDNA
per 51	LF 134		2 207
	L P160		5.251
	I P161	GTTATTACTGAACATCGTGAAATTAGCGTGCCT	n I\\/76
		G	5 110
	P133		0.110
1			

	LP136	AACGGTACTTGATCCGAATGTTC	pJW76
	LP137	GGAATTCCTCCTGTTAGCCC	5.545
pPI16	26	TTTTTGGGCTAACAGGAGGAATTCCATGAATAT GACACGTAACCATACATCC	X. indica gDNA 3.098
	29	GTGAGTGCCCGCCAAGCTCAAAGAAATGATCG TGGCGACCGACAC	
	12	TTCTTTGAGCTTGGCGGGC	X. doucetiae
	AL13-2	ATCCACCAGCAGTTGTTGTCG	gDNA 1.536
	40	GGAGCGACAACAACTGCTGGTGGATTGGAATG CAACCGCAACC	<i>P. luminescens</i> subsp. laumondii
	AT_492	GATAGGGGGTTTCTGTCGCGTTCCAAGTTTCCA ATAACAACTTGCGCTC	TT01 gDNA 3.203
	AT_226	TGGAACGCGACAGAAACC	P. luminescens
	9	ATTATCGTGTCGGCCGATTTGCTC	subsp. laumondii TT01 gDNA 1.668
	14	AAATCGGCCGACACGATAATTTTTTCAATATCG GAGGACATTCGC	X. indica gDNA 1.383
	6	TATACGAGCCGATGATTAATTGTCATTACTTATA TTCCGGTTCATATTTTTGTCC	
	pACYC-2	TGACAATTAATCATCGGCTCG	pJW75
	pACYC-1	GGAATTCCTCCTGTTAGCC	5.220
pPI16_XUT	26	TTTTTGGGCTAACAGGAGGAATTCCATGAATAT GACACGTAACCATACATCC	X. indica gDNA 3.098
	29	GTGAGTGCCCGCCAAGCTCAAAGAAATGATCG TGGCGACCGACAC	
	12	TTCTTTGAGCTTGGCGGGC	X. doucetiae
	AL13-2	ATCCACCAGCAGTTGTTGTCG	1.536
	40	GGAGCGACAACAACTGCTGGTGGATTGGAATG CAACCGCAACC	<i>P. luminescens</i> subsp. laumondii
	AT_492	GATAGGGGGTTTCTGTCGCGTTCCAAGTTTCCA ATAACAACTTGCGCTC	TT01 gDNA 3.203
	AT_226	TGGAACGCGACAGAAACC	P. luminescens
	LP356	AATTTGGCGAGCAAAAGCATCC	TT01 gDNA 1.578
	LP357	AGAGGATGCTTTTGCTCGCCAAATTTCTGAGGA ACGTCTGACTTC	X. indica gDNA 1.478
	6	TATACGAGCCGATGATTAATTGTCATTACTTATA TTCCGGTTCATATTTTTGTCC	
	pACYC-2	TGACAATTAATCATCGGCTCG	pJW75
	pACYC-1	GGAATTCCTCCTGTTAGCC	5.220
pPI16_type II	26	TTTTTGGGCTAACAGGAGGAATTCCATGAATAT GACACGTAACCATACATCC	X. indica gDNA 3.098
	29	GTGAGTGCCCGCCAAGCTCAAAGAAATGATCG TGGCGACCGACAC	
	12	TTCTTTGAGCTTGGCGGGC	X. doucetiae
	AL13-2	ATCCACCAGCAGTTGTTGTCG	gDNA 1.536

	40	GGAGCGACAACAACTGCTGGTGGATTGGAATG	P. luminescens
	AT 100		
	AT_492	GATAGGGGGTTTCTGTCGCGTTCCAAGTTTCCA	TTUT gDNA
		ATAACAACTTGCGCTC	3.203
	AT_226	TGGAACGCGACAGAAACC	P. luminescens
	I D358	CAAGGCAAAAAATTATCGTGTCGGC	subsp. laumondii
	LF 330	CAAGGCAAAAAATTATCGTGTCGGC	TT01 gDNA
			1.680
	LP359	CCGACACGATAATTTTTTTGCCTTGGGAGGACA	X. indica gDNA
		TTCGCTATTAGC	1.376
	6	TATACGAGCCGATGATTAATTGTCATTACTTATA	
	0	TTCCGGTTCATATTTTTGTCC	
			m 1\\/7E
	PACYC-2	IGACAATTAATCATCGGCTCG	pJvv75
	pACYC-1	GGAATTCCTCCTGTTAGCC	5.220
	p		
pPI16_end	26	TTTTTGGGCTAACAGGAGGAATTCCATGAATAT	X. indica gDNA
		GACACGTAACCATACATCC	3.098
	29	GTGAGTGCCCGCCAAGCTCAAAGAAATGATCG	
	-	TGGCGACCGACAC	
	12	TTCTTTGAGCTTGGCGGGC	X doucetiae
	12		
	AL13-2	ATCCACCAGCAGTTGTTGTCG	1 526
			1.550
	40		D /
	40	GGAGLGALAALAALIGLIGGIGGAIIGGAAIG	P. luminescens
		CAACCGCAACC	subsp. laumondii
	AT_492	GATAGGGGGTTTCTGTCGCGTTCCAAGTTTCCA	TT01 gDNA
		ATAACAACTTGCGCTC	3.203
	AT_226	TGGAACGCGACAGAAACC	P. luminescens
	L P360	TGCGCAGATTTTCTCGGTAAATGTCGCC	subsp. laumondii
	LI 300		TT01 gDNA
			1.803
	LP361	GACATTTACCGAGAAAATCTGCGCATATCTGAA	X. indica gDNA
		ТААТААТСАААААААСААТААСGAAATG	1.250
	6	TATACGAGCCGATGATTAATTGTCATTACTTATA	
		TTCCGGTTCATATTTTTGTCC	
	nACYC-2	TGACAATTAATCATCGGCTCG	pJW75
	p/ 10 1 0 2		5 220
	pACYC-1	GGAATTCCTCCTGTTAGCC	0.220
pCK 0678	ck002	CATGGAATTCCTCCTGTTAG	pCK 0401
P	ck0467	CATCAGGATATGTTAATTAACCTAGGCTGCTGC	3 672
		CAC	0.072
	ck0436b		X mauloonii
	00-000		
	-1-0.400		
	CKU468		3.113
	CKU465	CCTAGGITAATTAACATATCCTGATGGGCTTTG	X. mauleonii
		GCICCIG	gDNA
	ck0468	TTCCCGCAAAGCTTGGTAGGTTTCTGAC	6.992
pCK_0679		Mlul/SnaBl	pCK_0678
			12.499
	ck0459	CAAAGCGGGACCAAAGCCATG	pCK_0401
	ck0460	TGAGACCTTTTTTGGTCTCGGAATTCCTCCTGT	230
		TAG	
	ck0471	CCGAGACCAAAAAAGGTCTCACCCCTTGAATA	pCK 0678
		CAAGGCGTTGC	365
	ck0472	CCCGTTCGCTGGGATATTCTGG	

pCK_0680		Ncol/Pacl	pCK_0678
NRPS-19	-1-0.400h		14.247
	CKU469D		
	ck0470		12 632
		TTTG	12.002
pCK 0681		Mlul/Ascl	pCK 0680
P			12.905
	ck0594	GGCACCACCGATATACAGTTCACC	pCK_0680
	ck0463b	AGGAATTCCATGACAAAATCTGAATATTTAGTAA	2.520
		GTTCA	pCK_0401
	ck0459	CAAAGCGGGACCAAAGCCAIG	230
	CKU460	TAG	
pCK_0682	ck0455	CTGTGATATCAGCCAATTAATTAACCTAGGCTG	pCK_0401
		CTGCCAC	3.681
	ck0456	GATCTCATGGAATTCCTCCTGTTAGCCCA	
	ck0451	TTTGGGCTAACAGGAGGAATTCCATGAGATCAT	X. innexi aDNA
		TTGAG-GATTCACTGA	10.179
	ck0452	GGGTCTTTAGACCACCCGATTGC	
	ck0453	GCGCAATCGGGTGGTCTAAAGAC	X. innexi gDNA
	ck0454	CTAGGTTAATTAATTGGCTGATATCACAGTGCT	3.904
			- OK 0000
		Bgili/Avrii	pCK_0682
NKF 3-0			17.304
	ck0457	GAACCAAACAGGGTTATCGTCAGTGC	X. innexi aDNA
	ck0522	TGCTCAGCGGTGGCAGCAGCCTAGGTTAATTTA	8.441
		CGCCAATACCTTTTCCTGAC	
pCK_0684		AvrII/Ascl	pCK_0682
			12.549
	ck0454	CTAGGTTAATTAATTGGCTGATATCACAGTGCT	pCK_0682
	ak0460	GIAAIGG	3693
	CKU46U		
			nCK 0682
	ck0461b	CAGGATAAAC	174
	ck0462	TGTCATCAGATGATGCGCCAGTTGG	
pCK_0685		BgIII/AvrII	pCK_0684
			16.242
	ck0457	GAACCAAACAGGGTTATCGTCAGTGC	X. innexi gDNA
	ck0523	TATTGCTCAGCGGTGGCAGCAGCCTAGGTTAAT	8.444
			- OK 0005
		BSal/Adtii	PUK_0685
NICE 3-9a	ck0618	TATGTTGCCCCCGTAACGCA	20.445 nCK 0683
	ck0592	AATATAAGCAGCCATATCGCTGAGCG	2.658
	ck0475	TTTTTTGGGCTAACAGGAGGAATTCAATGAGA	<i>X. bovienii</i> gDNA
		ACATCTGAAAGCTCGTTG	3.003
	ck0635		
DOK 0764			
NRPS-9b		DSal/Adll	20.443

ck0592 AATATAAGCAGCCATATCGCTGAGCG 2.55	0
	0
	2 YDINA
	Ζ
GGAAAAGTTA	005
pCK_0/62 Bsal/Aatil pCK_0	685
NRPS-10a 20.44	13
ck0618 IATGTIGCCCCCCGTAACGCA pCK_0	683
ck0592 AATATAAGCAGCCATATCGCTGAGCG 2.65	8
Ck0477 TTTTTTGGGCTAACAGGAGGAATTCAATGAGA X. douc	etiae
ATACCTGAAGGTTCGT gDN	A
ck0637 TGCGTTACGGGGGGGCAACATAACTGTCCCGGT 2.99	7
TTTCCCATACG	
pCK_0763 Bsal/AatII pCK_0	685
NRPS-10b 20.44	13
ck0617 AATTCCCTGAGCGCCATTAAGCTG pCK 0	683
ck0592 AATATAAGCAGCCATATCGCTGAGCG 2.55	0
ck0477 TTTTTTGGGCTAACAGGAGGAATTCAATGAGA X. douc	etiae
ATACCTGAAGGTTCGT aDN	A
ck0638 GCTTAATGGCGCTCAGGGAATTGCCACCGATA 3 10	6
CGGAAAAATTATCC	0
nCK 0768 Bsal/Aatll nCK 0	685
NRPS-11a 20.4/	13
	683
	8 8
	0 K71
	Γ\7.4 Λ
	A 2
	3
	005
pCK_0/69 Bsal/Aatii pCK_0	685
NRPS-110 20.44	13
	683
CKU592 AATATAAGCAGCCATATCGCTGAGCG 2.55	0
ck0487 I I I I I I I GGGC I AACAGGAGGAA I I CAA I GAGA X. sp. K	K7.4
AAAGCTGAGGATCATTTGAA gDN.	A
ck0649 GCTTAATGGCGCTCAGGGAATTGCCGCCGATA 3.05	2
CGGAAGAAATTATC	
pCK_0820 Bsal/AatII pCK_0	685
NRPS-12a 20.44	13
ck0618 TATGTTGCCCCCGTAACGCA pCK_0	683
ck0592 AATATAAGCAGCCATATCGCTGAGCG 2.65	8
ck0708 TTTTTTGGGCTAACAGGAGGAATTCAATGAAT X. indi	ica
CACCCTGAAAATATGAAAC gDN	A
ck0717 TGCGTTACGGGGGGGCAACATATTCTTGTGTGAT 3.03	0
TACTGCTGAATG	
pCK 0822 Bsal/Aatll pCK 0	685
NRPS-13a 20.44	13
ck0618 TATGTTGCCCCCGTAACGCA pCK 0	683
ck0592 AATATAAGCAGCCATATCGCTGAGCG 265	8
	-
ck0711 TTTTTTGGGCTAACAGGAGGAATTCAATGAAC Serratia sr	D. SCBI
	A
ck0719 401	1

		TGCGTTACGGGGGGGCAACATAGTTTTCACGCAT	
PCK_0823		Bsal/Aatii	pCK_0685
NRPS-13D	10047		20.443
	CKU617		pCK_0683
	CK0592		2.550
	CKU711		Serratia sp. SCBI
	1.0700		gDNA 4400
	CKU720	CGAAGAAG	4120
pCK_0824		Bsal/AatlI	pCK_0685
NRPS-14a			20.443
	ck0618	TATGTTGCCCCCGTAACGCA	pCK_0683
	ck0592	AATATAAGCAGCCATATCGCTGAGCG	2.658
	ck0714	TTTTTTTGGGCTAACAGGAGGAATTCAATGAAG	P. lurida
		CATTCCACCCGCC	gDNA
	ck0721	TGCGTTACGGGGGGGCAACATACAGGCGAGTGA	2.877
pCK 0825		Bsal/Aatll	pCK 0685
NRPS-14b			20.443
	ck0617	AATTCCCTGAGCGCCATTAAGCTG	pCK 0683
	ck0592	AATATAAGCAGCCATATCGCTGAGCG	2.550
	ck0714	TTTTTTTGGGCTAACAGGAGGAATTCAATGAAG	P. lurida
		CATTCCACCCGCC	gDNA
	ck0722	GCTTAATGGCGCTCAGGGAATTCCCGCCGAGT	2.986
		TCAAAGAAG	
pCK_0826		Bsal/Aatll	pCK_0685
NRPS-15a			20.443
	ck0618	TATGTTGCCCCCGTAACGCA	pCK 0683
	ck0592	AATATAAGCAGCCATATCGCTGAGCG	2.658
	ck0723	TTTTTTGGGCTAACAGGAGGAATTCAATGGAT	X. bovienii gDNA
		AACATTCTGGCCTCG	2.877
	ck0729	TGCGTTACGGGGGGGCAACATAAACATAGCGGC	
		TCTGTTTAAAATC	
pCK_0827		Bsal/Aatll	pCK_0685
NRPS-15b			20.443
	ck0617	AATTCCCTGAGCGCCATTAAGCTG	pCK_0683
	ck0592	AATATAAGCAGCCATATCGCTGAGCG	2.550
	ck0723	TTTTTTTGGGCTAACAGGAGGAATTCAATGGAT	X. bovienii gDNA
		AACATTCTGGCCTCG	2.986
	ck0730	GCTTAATGGCGCTCAGGGAATTGCCCCCCAGA	
		TGAAAAAGT	
pCK_0828		Bsal/Aatll	pCK_0685
NRPS-16			20.443
	ck0618	TATGTTGCCCCCGTAACGCA	pCK_0683
	ck0592	AAIAIAAGCAGCCATATCGCTGAGCG	2.658
	ck0726		B. subtilis 168
	10701		gDNA
	ck0/31		2.925
	1.0000		014 0 400
pCK_0868	CKU828		pCK_0406
	CK0829		3.1/3
	ck0785b		M. xanthus gDNA
	1.000-		3.281
	ck0867	ACTICCGCTTCGGGAAGGACAATCT	

	ck0866	AGATTGTCCTTCCCGAAGCGGAAGT	M. xanthus gDNA
	ck0868	TGGCAGCAGCCTAGGTTAATTAATGGTGTACTC	3.261
		ATGCTGTCTCCCTCT	
pCK_0870		Bsal/AatII	pCK_0681
NRPS-20b	10707	000000000000000000000000000000000000000	21.482
	CKU/8/	GGCGGCAATTCCCTGATGG	pCK_0680
	CKU788		2135
	CKUOZU		
			3 055
	ck0822		0.000
pCK 0873	ONOOLL	Bsal/Aatl	pCK 0685
P			20.451
	ck0870	TTGGGCTAACAGGAGGAATTCAATGAGTACACC	M. xanthus gDNA
		AGCTGACAACATGAA	4.375
	ck0798	TTCCTGTGCGTTACGGGGGGGCAACGTAGGCCG	
		TCTCCAGG	pCK_0683
	ck0790	GTTGCCCCCGTAACGCA	2.665
	ck0592	AATATAAGCAGCCATATCGCTGAGCG	
pSB002		Bsal/AatII	pCK_0685
NRPS-18b	10047		20.443
	CKU617	AATTCCCTGAGCGCCATTAAGCTG	pCK_0683
	CKU592		2.550 X azantirmaii
	58001		
	SB003		GDNA 6.400
	30003		0.490
nCK 0881	ck0828	TTAATTAACCTAGGCTGCTGCCACC	nCK 0401
port_0001	ck0921	CATTGAATTCCTCCTGTTAGCCCAAA	3 669
	ck0857	CGAGACCAAAGAAGAAGGTCTCAGCTGCACCG	P. luminescens
		CAAGGAGAAACCGAAAC	subsp. laumondii
	ck0886	TTGCTCAGCGGTGGCAGCAGCCTAGGTTAATTA	TT01 gDNA
		ATTACAGCGCCTCCGCTTCACAATTCATTG	4.365
	ck0873	TTTGGGCTAACAGGAGGAATTCAATGAAAGATA	P. luminescens
		GCATGGCTAAAAAGGAA	subsp. laumondii
	ck0874	TGAGACCTTCTTCTTTGGTCTCGATAAATTTGGC	TT01 gDNA
		GAGCAAAAGCATC	4.993
pCK_0882	ck0828	TTAATTAACCTAGGCTGCTGCCACC	pCK_0401
	ck0921	CATTGAATTCCTCCTGTTAGCCCAAA	3.669
	CK0860		P. Iuminescens
	00006		
	CKUOOO		1 10 1 gDINA 1 266
	ck0873	TTTGGGCTAACAGGAGGAATTCAATGAAAGATA	P luminescens
	CK0075	GCATGGCTAAAAAGGAA	subsp laumondii
	ck0875	TGAGACCTTCTTCTTTGGTCTCGCAAGGCAAAA	TT01 aDNA
		AAATTATCGTGTCGG	5.092
pLS 002		Bsal	pCK 0882
· _ ·			12.921
	ls06	GCCGACACGATAATTTTTTGCCTTGGGCGGGC	M. xanthus gDNA
		ACTCGCTGCTCGCGAT	3.194
	ls07	TACCGCAAGCAACGAATGGCCCCCCAAGTCGA	
		AGAAGTTGTCCTCCGCG	
pLS_003		Bsal	pCK_0881

			12.921
	Is08	GCTTTTGCTCGCCAAATTTATGAGCCGCCTCGC ACGCCTA	<i>M. xanthus</i> gDNA 3.189
	ISU9	TCTCGCTCGCG	
pLS_008		Bsal	pCK_0882 12.921
	ls24	CGACACGATAATTTTTTTGCCTTGGGCGGCCAC TCCTTGCTGGC	<i>C. crocatus</i> gDNA 3.200
	ls25	ACCGCAAGCAACGAATGGCCCCCCAGCGCGAA GAAGTCGTCCTGC	
pLS_009		Bsal	pCK_0881 12.921
	ls26b	GGATGCTTTTGCTCGCCAAATTTATGTCACGCC CCGCACGCC	<i>C. crocatus</i> gDNA 3.205
	ls27b	GGTTTCGGTTTCTCCTTGCGGTGCAGCGAACTC GAAAGCTCCCTCGGCA	
pLS_017		Bsal	pCK_0882 12.921
	ls52	CCGACACGATAATTTTTTTGCCTTGGGTGGCCA TTCATTACTCGCTG	<i>X. indica</i> gDNA 3.241
	ls53	TACCGCAAGCAACGAATGGCCACCGAGTTCGA AGAAGTGGTCATAACG	
pLS_018		Bsal	pCK_0881 12.921
	ls68	GCTTTTGCTCGCCAAATTTATGAAGCGCCCATT GGCAAATTGGAA	<i>X. indica</i> gDNA 3.241
	ls55	CGGTTTCTCCTTGCGGTGCAGCATAGCCACGT GTAACAACCGCTG	
pLS_019		Bsal	pCK_0882 12.921
	ls60	GAGGATGCTTTTGCTCGCCAAATTTATCAAGCG CCGGAAAGCCCAATGGA	<i>X. mauleonii</i> gDNA
	ls61	GGTTTCGGTTTCTCCTTGCGGTGCAGCATATTG ACTCAATACAAACGCGGATGGC	3.288
pLS_0191	ls71_1 ls74_1	GGTGGCCATTCGTTGCTTGCG CAGGTGCTACATTTGAAGAGATAAATTGC	pCK_0882 6.395
	ls73	CTCTTCAAATGTAGCACCTGAAGTCAGC	pCK_0882
	ls72_1		6.546
	ls62	CGGCCGACACGATAATTTTTTTGCCTTGGGCGG CCATTCATTGCTTG	X. mauleonii gDNA
	ls63	CGTACCGCAAGCAACGAATGGCCACCCAATTC AAAGAAATGATCATGGCGAC	3.288

Peptide	MS detected	MS calculated	Molecular	∆ppm	Reference
	[M+H]⁺	[M+H]⁺	ion formula		
1	444.3061	444.3068	$C_{22}H_{42}N_3O_6$	1.5	synthetic
1	444.3062	444.3068	$C_{22}H_{42}N_3O_6$	1.3	
2	430.2911	430.2912	$C_{21}H_{40}N_3O_6$	0.1	
3	416.2750	416.2755	C ₂₀ H ₃₈ N ₃ O ₆	1.3	
4, 5	767.3932	767.3974	$C_{39}H_{55}N_6O_{10}$	5.5	isolated NP
6	783.3912	783.3923	$C_{39}H_{54}N_6O_{11}$	1.4	
7	811.4217	811.4236	$C_{41}H_{58}N_6O_{11}$	2.4	
8	839.4531	839.4549	$C_{43}H_{62}N_6O_{11}$	2.2	
9	783.3912	783.3923	$C_{39}H_{54}N_6O_{11}$	0.9	
10	811.4219	811.4236	$C_{41}H_{58}N_6O_{11}$	2.1	
11	839.4531	839.4549	$C_{43}H_{62}N_6O_{11}$	2.2	
12	782.4071	782.4083	C ₃₉ H ₅₅ N ₇ O ₁₀	1.6	
13	810.4375	810.4397	C41H59N7O10	2.6	
14	838.4680	838.4710	C43H63N7O10	3.5	
15	753.3808	753.3818	$C_{38}H_{52}N_6O_{10}$	1.3	
16	869.4631	869.4655	$C_{44}H_{64}N_6O_{12}$	2.8	
17	867.4833	867.4862	$C_{45}H_{66}N_6O_{11}$	3.4	
18	895.5143	895.5175	C47H70N6O11	3.6	
19	725.3855	725.3869	$C_{37}H_{52}N_6O_9$	1.9	
20	993.5499	993.5543	$C_{52}H_{76}N_6O_{13}$	4.4	
21	995.5662	995.5700	C52H78N6O13	3.8	
22	977.5557	977.5594	$C_{52}H_{76}N_6O_{12}$	3.8	
23	979.5715	979.5751	C52H78N6O12	3.6	
24	955.4986	977.5019	$C_{54}H_{68}N_6O_{11}$	3.3	
25	836.4167	836.4888	C42H57N7O11	2.6	
26	799.4429	799.4461	C ₃₈ H ₅₈ N ₁₀ O ₉	4.0	Isolated NP
27	813.4579	813.4618	C ₃₉ H ₆₀ N ₁₀ O ₉	4.7	
28	913.5475	913.5506	$C_{45}H_{72}N_{10}O_{10}$	3.4	
29	941.5780	941.5819	C47H76N10O10	4.1	
30	931.5573	931.5611	C45H74N10O11	4.1	
31	945.5728	945.5768	C46H76N10O11	4.2	
32	959.5892	959.5924	C47H78N10O11	3.4	
33	973.6033	973.6080	C48H80N10O11	4.9	
34	457.3378	457.3384	C ₂₃ H ₄₄ N ₄ O ₅	1.3	synthetic
35	471.3534	471.3541	C ₂₄ H ₄₆ N ₄ O ₅	1.4	
36	431.2857	431.2864	C ₂₀ H ₃₉ N ₄ O ₆	1.6	synthetic
37	445.3010	445.3021	C ₂₁ H ₄₁ N ₄ O ₆	1.7	
38	415.2910	415.2915	C ₂₀ H ₃₉ N ₄ O ₅	1.2	synthetic
39	429.3064	429.3071	C ₂₁ H ₄₁ N ₄ O ₅	1.8	
40	511.3845	511.3854	C ₂₇ H ₅₁ N ₄ O ₅	1.7	
41	525.3998	525.4010	C ₂₈ H ₅₃ N ₄ O ₅	2.3	
42	539.4159	539.4167	C ₂₉ H ₅₅ N ₄ O ₅	1.5	
43	458.3218	458.3225	C23H44N3O6	1.5	

 Table S5. Detected compounds in this work.

Table S6. ¹H (500 MHz) and ¹³C (125 MHz) NMR data of compound **1** in DMSO-d₆ (δ in ppm). COSY (bold) and key HMBC (arrows) are shown.



Position	δc, typea	δ н, mult. (<i>J</i> in Hz)
1	13.86, CH₃	0.88-0.79, ov
2	21.90, CH ₂	1.31-1.81, m
3	30.85, CH ₂	1.31-1.81, m
4	25.00, CH ₂	1.64-1.42, m
5	35.10, CH₂	2.17, m
6	172.54, C	-
7	57.85, CH	4.26, dd (12.0, 6.0)
7NH	-	7.70, d (8.32)
8	66.44, CH	3.95, m
9	19.39, CH₃	1.01, d (6.34)
10	169.76, C	-
11	50.90, CH	4.35, dd(15.0, 8.4)
11NH	-	7.81, d (8.53)
12	41.01, CH ₂	1.64-1.42, ov
13	24.27 – 24.03, CH	1.64-1.42, ov
14	-	0.88-0.79, ov
15	-	0.88-0.79, ov
16	171.82, C	-
17	50.10, CH	4.20, ddd (10.0, 8.3, 4.8)f
17NH	-	8.03, d (8.19)
18	40.04, CH ₂	1.64-1.42, ov
19	24.27 – 24.03, CH	1.64-1.42, ov
20	-	0.88-0.79, ov
21	-	0.88-0.79, ov
22	173.92, C	-

		4		5
no.	δ _c , type	δ _H (mult., <i>J</i>)	$\delta_{\rm C}$, type	$\delta_{\rm H}$ (mult., J)
1	169.4		169.4	
2		6.69 (d, 5.7)		7.06 (d, 5.7)
3	37.1	3.46 (td, 13.0, 5.6)	36.9	3.46 (td, 12.8, 5.8)
		3.31 (m)		3.34 (m)
4	34.3	2.52 (m)	34.4	2.54 (m)
_		2.23 (m)		2.22 (m)
5	173.3		173.6	
6		8.50 (d, 4.4)		8.38 (d, 5.1)
7	57.4	4.25 (m)	57.4	4.30 (m)
8	35.3	2.61 (dd, 14.4, 4.8)	35.3	2.64 (m)
0	107.0	2.34 (00, 14.4, 3.7)	100.0	2.37 (dd, 14.0, 2.2)
9	127.0	7.04 (d. 9.2)	120.0	707(d 92)
10	130.2	6 71 (d. 8 3)	130.1	6 73 (d. 8 3)
12	156.6	0.71 (d; 0.0)	156.6	0.73 (d, 0.0)
13	115.6	6 71 (d. 8 3)	115.6	6 73 (d. 8 3)
14	130.2	7 04 (d. 8.3)	130.1	7 07 (d. 8.3)
15	174.6	1.0 T (d; 0.0)	174.6	1.07 (d, 0.0)
16		8.76 (d. 8.7)		8.97 (d. 8.4)
17	54.4	4.81 (m)	55.0	4.62 (m)
18	34.9	3.17 (dd, 14.2, 3.2)	35.0	3.24 (dd, 14.0, 3.2)
		2.65 (m)		2.64 (overlap)
19	128.4		128.5	
20	130.3	7.02 (d, 8.3)	130.3	7.06 (d, 8.4)
21	115.1	6.58 (d, 8.3)	115.2	6.60 (d, 8.4)
22	156.1		156.2	
23	115.1	6.58 (d, 8.3)	115.2	6.60 (d, 8.4)
24	130.3	7.02 (d, 8.3)	130.3	7.06 (d, 8.4)
25	171.8		171.7	
26	54.0	7.40 (d, 8.1)	54.0	7.36 (d, 7.9)
27	51.9	4.17 (ddd, 12.0, 8.1, 4.2)	51.9	4.17 (ddd, 11.9, 8.0, 4.2)
28	39.2	1.82 (m)	39.3	1.81 (M)
20	24.6	1.40 (m)	24.6	1.42 (ff)
29	24.0	1.74 (III) 0.82 (d. 6.5)	24.0	
21	21.1	0.03(0, 0.3)	21.1	0.04 (0, 0.4)
32	23. 4 171 7	0.00 (d; 0.0)	23.0	0.00(0; 5.2)
33	72.0	5.11 (ad 6.2 1.8)	72 1	5.12 (ad $6.1.1.7$)
34	16.0	1 02 (d 6 2)	16.0	1.04 (d 6.1)
35	56.2	4 46 (dd 10 2 1 8)	56.4	4 44 (m)
36	00.2	7.97 (d. 10.2)	0011	7.88 (d. 10.1)
37	173.1	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	173.9	
38	56.9	4.33 (dd, 10.5, 8.6)	51.6	4.42 (m)
39	35.2	1.86 (overlap)	39.8	1.54 (m)
40	24.7	1.44 (overlap)	24.6	1.60 (m)
		1.20 (m)		
41	10.2	0.74 (t, 7.4)	21.1	0.62 (d, 6.4)
42	15.8	0.91 (d, 6.8)	23.4	0.90 (d, 5.9)
43	· • • -	8.00 (d, 8.6)	· •	8.01 (d, 7.9)
44	169.5		169.5	
45	22.8	1.83 (s)	22.8	1.81 (s)

Table S7. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectroscopic data of compounds **4** and **5** in DMSO- d_6 (δ in ppm and J in Hz).

		7		10
no.	δ _c , type	δ _H (mult., J)	δ _c , type	δ⊢ (mult., <i>J</i>)
1	170.3		169.0	x
2		7.03 (m)		6.93 (m)
3	35.1	3.39 (m)	36.7	3.50 (m)
		3.21 (m)		3.20 (m)
4	34.4	2.37 (m)	34.1	2.50 (m)
		2.19 (m)		2.26 (m)
5	172 2		173 0	()
6		8 20 (d. 6 6)		8 38 (d. 4 6)
7	56.4	4.22 (m)	57.2	4.28 (m)
8	36.1	2 54 (m)	35.5	2 65 (m)
U	0011	2.01 ()	0010	2 42 (dd 14 2 3 8)
9	128 2		127 8	2.12 (33, 1.12, 515)
10	130.4	6 94 (d. 8 4)	130.2	7 08 (d. 8 4)
11	115.4	6 65 (d 8 4)	115.6	6.72 (d. 8.4)
12	156.4	0.00 (0, 0.4)	156.6	0.72 (d, 0.4)
13	115.4	6 65 (d. 8 4)	115.6	672 (d. 84)
14	130.4	6.00(d, 0.4)	130.2	7.08 (d, 8.4)
15	170.4	0.04 (0, 0.4)	17/ 8	7.00 (d; 0.4)
16	172.2	8 20 (d 8 0)	174.0	8 80 (d 8 4)
17	55 1	4.22 (m)	55.0	4.40 (m)
10	36.0	4.52 (III) 3.02 (dd 13.0, 3.8)	35.0	4.49 (III) 2.11 (dd 14 0 2 0)
10	30.0	3.02 (dd, 13.9, 3.0)	33.5	2.65 (m)
10	100 6	2.00 (00, 13.9, 10.4)	100 5	2.05 (11)
19	120.0	607(d, 95)	120.0	7 04 (d 9 4)
20	130.4	0.97 (0, 0.3)	130.4	7.04 (0, 0.4)
21	110.4	0.05 (u, o.5)	110.0	0.02 (u, o.4)
22	100.3		100.3	
23	110.4	0.00(0, 0.0)	110.3	0.02 (0, 0.4)
24	130.4	6.97 (0, 8.5)	130.4	7.04 (0, 8.4)
20	171.8		171.0	7 40 (1 7 0)
20		7.57 (0, 7.9)	54.0	7.40 (d, 7.9)
27	51.5	4.32 (overlap)	51.9	4.13 (m)
28	39.6	1.67 (m)	39.4	1.78 (m)
00	04.5	1.51 (m)	04.5	1.41 (m)
29	24.5	1.67 (overlap)	24.5	1.73 (m)
30	22.0	0.86 (d, 6.3)	21.2	0.84 (d, 7.0)
31	22.3	0.90 (d, 6.3)	23.3	0.88 (d, 6.5)
32	1/1.5		1/1.6	
33	/1.4	5.21 (qd, 6.3, 3.5)	/1.5	5.20 (qd, 6.4, 2.1)
34	16.9	1.06 (d, 6.3)	16.1	1.04 (d, 6.4)
35	54.9	4.70 (dd, 9.3, 3.5)	56.2	4.50 (dd, 9.8, 2.1)
36		7.78 (d, 9.3)		7.69 (d, 9.8)
37	173.2		171.6	
38	35.5	2.19 (overlap)	57.9	4.48 (dd, 8.6, 3.0)
39	25.5	1.51 (overlap)		7.63 (d, 8.6)
40	31.4	1.21 (m)	172.9	
41	22.3	1.25 (m)	35.1	2.08 (m)
42	14.3	0.84 (t, 7.0)	25.4	1.47 (m)
43	169.8		31.3	1.20 (m)
44		7.93 (d, 7.6)	22.4	1.26 (m)
45	59.6	3.93 (dd, 7.6, 3.8)	14.4	0.84 (t, 7.0)
46	65.8	4.09 (m)	67.0	4.23 (m)
47	20.7	1.00 (d, 6.4)	20.1	1.07 (d, 6.3)

Table S8. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectroscopic data for compounds **7** and **10** in DMSO d_6 (δ in ppm and J in Hz).

Table S9. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectroscopic data for compound **26** in DMSO- d_6 (δ in ppm and J in Hz).

	26		
10.	$\delta_{\rm C}$, type	<i>δ</i> ⊣ (mult., <i>J</i>)	
1	157.7		
2		8.05 (t, 5.0)	
3	40.8	3.04 (m)	
4	25.6	1.54 (m)	
5	28.1	1.74 (m)	
6	53.7	4.01 (m)	
7	171.0		
9	69.9	5.00 (m)	
10	15.0	1.10 (d, 6.5)	
11	54.5	4.48 (dd, 8.4, 4.4)	
12		8.03 (d, 8.4)	
13	169.7		
14	22.8	1.90 (s)	
15	167.6		
16		8.75 (d, 9.2)	
17	55.6	4.62 (m)	
18	29.8	3.16 (dd, 14.4, 8.0)	
		2.99 (dd, 14.4, 6.7)	
19	109.9		
20	124.1	7.12 (d, 2.0)	
21		10.87 (d, 2.0)	
22	136.5		
23	111.7	7.32 (d, 8.1)	
24	121.3	7.05 (m)	
25	118.8	6.96 (m)	
26	118.6	7.54 (d, 7.9)	
27	127.8		
28	172.0		
29		8.56 (d, 4.7)	
30	61.0	4.19 (dd. 7.7. 4.7)	
31	66.0	3.91 (m)	
32	20.1	1.08 (d. 6.3)	
33	173.6		
34		8.73 (d. 5.7)	
35	60.9	3.88 (dd. 5.7. 4.7)	
36	29.1	2.18 (m)	
37	17.8	0.90 (d. 6.9)	
38	19.4	0.95 (d. 7.0)	
39	171.4		
40		6.83 (d. 8.0)	
41	56.7	4.19 (dd 8.0 4.9)	
42	35.5	1.87 (m)	
43	26.3	1 19 (m)	
	20.0	1 14 (m)	
44	11 9	0.77 (t 7.4)	
45	15.0	0.75 (d. 7.0)	
46	171.9	0.10 (0, 1.0)	
47	171.0	7 43 (d. 58)	
-T /		1. TO (U, D.O)	

Table S10. ¹H (500 MHz) and ¹³C (125 MHz) NMR data of compound **41** in DMSO-d₆ (δ in ppm). COSY (bold) and key HMBC (arrows) are shown.



Position	δc, typea	δ н, mult. (<i>J</i> in Hz)
1	-	0.91 – 0.80, ov
11	-	1.30 – 1.15, ov
12	25.19, CH₂	1.55 – 1.38, ov
13	35.15, CH ₂	2.15 – 2.03, ov
14	172.74, C	<u> </u>
15	52.33, CH	4.21 - 4.14, m
15NH	_	8.05 – 7.92, m
16	28.66, CH ₂	1.91 – 1.66, m
17	31.53, CH ₂	2.15 – 2.03, m
17NH	_	7.24 (s)
17NH	-	6.74 (s)
18	173.80, C	-
19	171.21, C	-
20	48.05, CH	4.33 – 4.21, m
20NH	-	8.05 – 7.92, m
21	18.19, CH₃	1.30 – 1.15, ov
22	172.56, C	-
23	56.54, CH	4.14 – 4.05, m
23NH	-	8.23 – 8.17, m
24	36.33, CH₂	1.55 – 1.38, ov
25	24.00, CH	2.15 – 2.03, ov
26	-	0.91 – 0.80, ov
27	-	0.91 – 0.80, ov
28	201.05, CH	9.39 – 9.35, m

yCPC14QAL
P21
a = 135.0 Å
b = 300.9 Å
c = 144.0 Å
β = 112.8 °
1
X06SA, SLS
1.0
50-3.25 (3-35-3.25)
481076
157953
95.1 (93.7)
10.5 (65.4)
11.1 (2.4)
30-3 25
149904
7890
49565
148
95
17.5 / 21.2
0.003 / 1.2
91.3
97.6 / 2.2 / 0.2
8BW1

 Table S11. Crystallographic data collection and refinement statistics of yCP:41.

^[a] Asymmetric unit

 $^{[b]}$ The values in parentheses for resolution range, completeness, $R_{\rm merge}$ and I/ σ (I) correspond to the highest resolution shell

^[c] Data reduction was carried out from a single crystal. Friedel pairs were treated as identical reflections ^[d] $R_{merge}(I) = \Sigma_{hkl}\Sigma_j | I(hkl)_j - \langle I(hkl) \rangle | / \Sigma_{hkl} \Sigma_j I(hkl)_j$, where $I(hkl)_j$ is the jth measurement of the intensity of reflection hkl and $\langle I(hkl) \rangle$ is the average intensity

 $^{[e]}R = \Sigma_{hkl} | |F_{obs}| - |F_{calc}| | \Sigma_{hkl} | F_{obs}|$, where R_{free} is calculated without a sigma cut off for a randomly chosen 5% of reflections, which were not used for structure refinement, and R_{work} is calculated for the remaining reflections

^[f] Deviations from ideal bond lengths/angles

^[g] Percentage of residues in favored / allowed / outlier region



Fig. S1. Evolutionary analysis of ATC tridomains and T domains of representative NRPS. (a) Likelihood difference plot of two phylogenetic trees of ATC tridomains (also called XUs) that together best describe the alignment using a phylogenetic hidden Markov model. Positive numbers indicate that sites are better describe by tree 1, negative numbers indicate sites that are better described by tree two. Protein structure of XU is shown below. A domain is colored in blue, T-domain in yellow and C domain in red. (b) Likelihood difference plot as in a, but for an alignment of T domain plus A-T linker. Partitions detected by the hidden Markov model are indicated in different colors according to tree number. Recombination breakpoint is annotated in grey and lies around two conserved glycines. Protein structure of A-T-Linker and T domain is shown below. The first part of the T domain is colored in yellow and the second part in orange. An arrow points to the fusion site used for engineering.



Fig S2. Comparison of Tree 1 and Tree 2 from the XU alignment. Taxon names indicate abbreviation of NRPSs, followed by bacterial species and then numbers of the XU within that NRPS. Lines connect the same NRPS and XU between the two trees. Red branches label XUs that contain ${}^{L}C_{L}$ domains and blue branches label XUs with CE (dual C) domains.



Fig. S3. Comparison of Tree 1 from XU domain alignment and Tree 1 from T domain alignment. Taxon names indicate abbreviation of NRPS, followed by bacterial species and then numbers of the XU within that NRPS. Lines connect the same NRPS and XU between the two trees. Red branches label ${}^{L}C_{L}$ domains and blue branches label CE (dual C) domains.





Tree 2 of T domain alignment

Fig S4. Comparison of Tree 1 from T domain alignment and Tree 2 from T domain alignment. Taxon names indicate abbreviation of NRPS, followed by bacterial species and then numbers of the XU within that NRPS. Lines connect the same NRPS and XU between the two trees. Red branches label ${}^{L}C_{L}$ domains and blue branches label CE (dual C) domains.

Tree 1 of XU alignment

Tree 2 of T domain alignment



Fig. S5. Comparison of Tree 1 from XU domain alignment and Tree 2 from T domain alignment. Taxon names indicate abbreviation of NRPS, followed by bacterial species and then numbers of the XU within that NRPS. Lines connect the same NRPS and XU between the two trees. Red branches label ${}^{L}C_{L}$ domains and blue branches label CE (dual C) domains.



Figure S6. Phylogenetic analysis of T-domains in relation to preceding A-domain and following C/CE-domain. In (**A**) a schematic representation of the PAX producing NRPS^{25,26} with the T3-domain under scrutiny highlighted (reddish square). The following CE4-domain is shown in blue and the C4-domain in red. In (**B**) a dual alignment of the A3-T3-CE4/C4 domains from *X. nematophila compared* to *X. doucetiae* can be seen. The amino acid alignment in the middle is shown with agreements in colour, genes as yellow bars and the domains indicated in the colour used in (**A**). The mean pairwise identity over all pairs in the column are calculated for a sliding window size 20 amino acids (green 100% identity, greenish-brown at least 30% under 100%, red below 30%). The drop of pairwise identity from high value between the A-domain region to the low identity between C- and CE-domains occurs in the middle of the T-domain. In (**C**) a phylogenetic tree of A3-, T3- second half (corresponds to T-fusion point IV in figure 2) and C4/CE4-domains is presented. The phylogenetic tree was calculated for the A3-domain, T3-domain second half and the following C/CE-domains separately. To this end multiple alignments of the protein sequences were generated using Clustal Omega 1.2.2.²⁷ with the refinement iterations number set at 10 while evaluating

the full distance matrix for the initial guide tree as well as for the refinement iteration guide tree. Only bootstrap values at critical junctions are indicated. The colours blue (CE) and red (C) refer to the condensation domains of the A3-T3-C4/CE4 unit. Abbreviations of the indicated PAX NRPS organisms: Xbud, *X. budapestensis*; Xbed, *X. beddingii*; Xbov, *X. bovienii*; Xdou, *X. doucetiae*; Xehl, *X. ehlersii*; X eap, *X. eapokensis*; Xhom, *X. hominickii*; Xind, *X. indica*; Xkho, *X. khoisanae*; Xkop, *X. koppenhoeferi*; Xkoz, *X. kozodoii*; Xmau, *X. mauleonii*; Xmir, *X. miraniensis*; Xnem, *X. nematophila*; Xsze, *X. szentirmaii*; Xthu, *X. thuongxuanensis* str. 30TX1, Xvie, *X. vietnamensis*, *X. sp.* KJ12.1, X KK7.4, *X.* sp. KK7.4, *X.* sp. PB30.3, X PB30.3). PaxABC sequences were identified using the PaxABC peptide sequences of *X. nematophila* and *X. doucetiae* as query. Domain annotation was implemented by use of AntiSMASH 6.0²⁸.



Aprior T-TE-domain tree

T^{⊤E} sec. half-domain <u>tree</u>

TE-domain tree

Figure S7. Phylogenetic analysis of T-domains in relation to preceding A-domain and the following TEdomain of the PAX-NRPS. The PAX biosynthesis in *Xenorhabdus* contains one of two types TE-domains being equally distributed in the *in silico* accessible biosynthesis. In (**A**) the final NRPS multienzymes are depicted with the *X. nematophila* TE-type in green and the *X. doucetiae* TE-type in purple. (**B**) A dual alignment of the A7-T7-TE unit from *X. nematophila* and *X. doucetiae* visualises the low identity between the two TE-types and that the drop of the sequence identity occurs in the middle of the T-domain. The phylogenetic tree in (**C**) was derived as described in Figure S6. The colour bars in all three phylogenetic trees refer to the TE in the A-T-TE unit. The *Xenorhabdus* species abbreviations are as in Figure S6.



Figure S8. Phylogenetic analysis of T-domains in relation to preceding A-domain and following C/CEdomain of RzmA and EpyDE. (**A**) Schematic representation of the endopyrrole A producing NRPS EpyDE²⁹ and the rhizomide A producing NRPS RzmA³⁰ from *Mycetohabitans rhizoxinica* (DSM 19002). In (**B**) the EpyDE A7-T7-C8 unit and the RzmA A3-T3-CE4 unit are shown in a dual alignment. The phylogenetic trees of the A-domains, the T-domain second half and the C/CE-domains of RzmA and EpyDE were generated separately as described in Figure S6 using the same colour code (**C**).



Figure S9. Phylogenetic analysis of T-domains in relation to preceding A-domain and following C/CEdomain of the syringopeptin SP-25a NRPS synthesis (SypABC; ALU60730.1, ALU60731.1, ALU60732.1) of *Pseudomonas syringae pv. lapsa* (DSM 50274) (**A**). The indicated A-domain substrate specificity was derived from published SP-25a³¹ in conjunction with AntiSMASH 6.0 predictions²⁸. In (**B**) two dual alignments of the SypA A7-T7-C8 to the SypB A11-T11-CE12 (top) and the SypC A20-T20-CE21 unit to the A22-T22-C23 (bottom) are shown. The phylogenetic trees of the A-domains, the T-domain second half and the C/CE-domains of SypABC were generated separately as described in Figure S6 using the same colour code (**C**).



Figure S10. ¹H NMR (500 MHz, DMSO-d₆) spectrum compound 1.



Figure S11. 13 C NMR (125 MHz, DMSO-d₆) spectrum of compound 1.


Figure S12. HSQC (DMSO-d₆) spectrum compound 1.



Figure S13. ¹H-¹H COSY (DMSO-d₆) spectrum of compound **1**.



Figure S14. HMBC (DMSO-d₆) spectrum of compound 1.



Figure S15. HPLC/MS data refers to Figure 2 (NRPS-1 to -7) of compound **1**, **2**, **3** and **43** produced in *E. coli* DH10B::*mtaA*. Base Peak Chromatogram (BPC, top) and Extracted Ion Chromatogram (EIC, below) of **1** (m/z [M+H]⁺ = 444.30), **2** (m/z [M+H]⁺ = 430.29), **3** (m/z [M+H]⁺ = 416.27) and **43** (m/z [M+H]⁺ = 458.32). Chromatograms were compared to an empty vector control and a synthetic standard of compound **1** (m/z [M+H]⁺ = 444.30).





Figure S16. HPLC/MS data refers to Figure 2 (NRPS-1, -3 and -4) of compound **1** (**A**) and **2** (**B**) produced in *E. coli* DH10B::*mtaA*. Comparison of MS² spectra. Compound **1** fragmentation was compared to a synthetic **1**.



Figure S17. HPLC/MS data refers to Figure 2 (NRPS-1, -3 and -4) of compound **3** (**A**) and **43** (**B**) produced in *E. coli* DH10B::*mtaA*. Comparison of MS² spectra.

NRPS	Peptide	Peptide	Organism	Donor BGC	Fusion site	Production (mg l ⁻¹)	% of NRPS-8
-19	26, 27	C2- T WTviR	X. mauleonii	ftrAB	WT	56.0 ±3.5	100
-20b	28 , 29	C10-βOH- S WTviR	S. marcescens	swrW	IV	2.5 ±0.2	4

Figure S18. (**A**) Domain architecture of Fatttvir (**FA** Thr Tyr Thr Val IIe a**R**g) producing FtrAB (NRPS-19) and NRPS-20b with their peptide product structures **26-33** shown below. Structure elucidation of **26** is shown at Figures S19 – S21 and S44 - S49. (**B**) For quantification the signal intensities for **28** and **29** were summarized and compared to the summarized amount of **26** and **27** in the WT.

Figure S19. Chromatograms and structures of 4, 5, 26 and 27 and their NRPS-engineering derivatives.

Figure S20. MS-spectra of peptides 4-33 of NRPS-8 to -20 corresponding to the extracted ion chromatograms in Fig. S19.

Figure S21. MS² spectra of peptides 4-33 of NRPS-8 to -20 corresponding to the signals in Fig. S20.

HMBC H- C 1H-1H COSYH H

Figure S22. Key HMBC and ¹H-¹H COSY correlations of compounds 4 and 5.

Figure S24. ¹³C NMR spectrum of compound 4.

Figure S25. HSQC spectrum of compound 4.

Figure S26. ¹H-¹H COSY spectrum of compound 4.

Figure S27. HMBC spectrum of compound 4.

Figure S28. ¹H NMR spectrum of compound 5.

Figure S29. ¹³C NMR spectrum of compound 5.

Figure S30. HSQC spectrum of compound 5.

Figure S31. ¹H-¹H COSY spectrum of compound 5.

Figure S32. HMBC spectrum of compound 5.

HMBC H→ C 1H-1H COSYH - H

Figure S33. Key HMBC and ¹H-¹H COSY correlations of compounds 7 and 10.

Figure S34. ¹H NMR spectrum of compound 7.

Figure S35. ¹³C NMR spectrum of compound 7.

Figure S36. HSQC spectrum of compound 7.

Figure S37. ¹H-¹H COSY spectrum of compound 7.

Figure S38. HMBC spectrum of compound 7.

Figure S39. ¹H NMR spectrum of compound 10.

Figure S40. ¹³C NMR spectrum of compound **10**.

Figure S41. HSQC spectrum of compound 10.

Figure S42. ¹H-¹H COSY spectrum of compound 10.

Figure S43. HMBC spectrum of compound 10.

Figure S44. Key HMBC and ¹H-¹H COSY correlations of compound 26.

Figure S45. ¹H NMR spectrum of compound 26.

Figure S46. ¹³C NMR spectrum of compound 26.

Figure S47. HSQC spectrum of compound 26.

Figure S48. ¹H-¹H COSY spectrum of compound 26.

Figure S49. HMBC spectrum of compound 26.

Figure S50. HPLC/MS data refers to Figure 4 (NRPS-21 and -23) of compound **34** and **35** produced in *E. coli* DH10B::*mtaA*. Base Peak Chromatogram (BPC, top) and Extracted Ion Chromatogram (EIC, below) of **34** (m/z [M+H]⁺ = 457.34) and **35** (m/z [M+H]⁺ = 471.35). Chromatograms were compared to an empty vector control and a synthetic standard of compound **34** (m/z [M+H]⁺ = 457.34).

Figure S51. a) HPLC/MS data refers to Figure 4 (NRPS-21 and -23) of compound **34** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **34** produced by NRPS-21 and -23 compared to a synthetic standard of compound **34**. **b**) HPLC/MS data refers to Figure 4 (NRPS-21 and -23) of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **35** produced by NRPS-21 and -23.

Figure S52. HPLC/MS data refers to Figure 4 (NRPS-22) of compound **36** and **37** produced in *E. coli* DH10B::*mtaA*. Base Peak Chromatogram (BPC, top) and Extracted Ion Chromatogram (EIC, below) of **36** (m/z [M+H]⁺ = 431.28) and **37** (m/z [M+H]⁺ = 445.30). Chromatograms were compared to an empty vector control and a synthetic standard of compound **36** (m/z [M+H]⁺ = 431.28).

Figure S53. a) HPLC/MS data refers to Figure 4 (NRPS-22) of compound **36** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **36** produced by NRPS-22 compared to a synthetic standard of compound **36**. b) HPLC/MS data refers to Figure 4 (NRPS-22) of compound **37** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **37** produced by NRPS-22.

Figure S54. HPLC/MS data refers to Figure 4 (NRPS-24) of compound **38** and **39** produced in *E. coli* DH10B::*mtaA*. Base Peak Chromatogram (BPC, top) and Extracted Ion Chromatogram (EIC, below) of **38** (m/z [M+H]⁺ = 415.29) and **39** (m/z [M+H]⁺ = 429.31). Chromatograms were compared to an empty vector control and a synthetic standard of compound **38** (m/z [M+H]⁺ = 415.29).

Figure S55. a) HPLC/MS data refers to Figure 4 (NRPS-24) of compound **38** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **38** produced by NRPS-24 compared to a synthetic standard of compound **38**. b) HPLC/MS data refers to Figure 4 (NRPS-24) of compound **39** produced in *E. coli* DH10B::*mtaA*. MS² and amino acid fragmentation of compound **39** produced by NRPS-24.

Figure S56. ¹H NMR (500 MHz, DMSO-d₆) spectrum compound **41**.

Figure S57. ¹³C NMR (125 MHz, DMSO-d₆) spectrum compound **41**.


Figure S58. HSQC (DMSO-d6) spectrum of compound 41.



Figure S59. ¹H-¹H COSY (DMSO-d6) spectrum compound 41.



Figure S60. HMBC (DMSO-d6) spectrum compound 41.



Figure 61. HPLC/MS data refers to Figure 5 (NRPS-25-28) of compound **40**, **41** and **42** produced in *E. coli* DH10B::*mtaA*. Base Peak Chromatogram (BPC, top) and Extracted Ion Chromatogram (EIC, below) of **40** (m/z [M+H]⁺ = 511.38), **41** (m/z [M+H]⁺ = 525.40), **42** (m/z [M+H]⁺ = 539.41). Chromatograms were compared to an empty vector control and a purified compound **42** standard (m/z [M+H]⁺ = 525.40).



Figure S62. HPLC/MS data refers to Figure 5 (NRPS-26) of compound **40** (A), **41** (B) and **42** (C) produced in *E. coli* DH10B::*mtaA*. Comparison of MS² spectra.



Figure S63. IC₅₀ determination of compound **41** (termed as C14-QAL(H)) for subunits beta1, -2 and -5 of yeast 20S proteasome (yCP).

References

- 1 Bode, E. *et al.* Promoter Activation in Δ hfq Mutants as an Efficient Tool for Specialized Metabolite Production Enabling Direct Bioactivity Testing. *Angewandte Chemie* **131**, 19133-19139, doi:10.1002/ange.201910563 (2019).
- 2 Bozhueyuek, K. A. J., Watzel, J., Abbood, N. & Bode, H. B. Synthetic Zippers as an Enabling Tool for Engineering of Non-Ribosomal Peptide Synthetases**. *Angewandte Chemie* **133**, 17672-17679, doi:10.1002/ange.202102859 (2021).
- 3 Gallastegui, N. & Groll, M. Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies. *Methods Mol Biol* **832**, 373-390, doi:10.1007/978-1-61779-474-2_26 (2012).
- 4 Groll, M. & Huber, R. Purification, crystallization, and X-ray analysis of the yeast 20S proteasome. *Methods Enzymol* **398**, 329-336, doi:10.1016/S0076-6879(05)98027-0 (2005).
- 5 Kabsch, W. XDS. Acta Crystallographica Section D Biological Crystallography **66**, 125-132, doi:10.1107/s0907444909047337 (2010).
- 6 Schneider, T. R. & Sheldrick, G. M. Substructure solution with SHELXD. Acta Crystallogr D Biol Crystallogr 58, 1772-1779, doi:10.1107/s0907444902011678 (2002).
- 7 Huber, E. M. *et al.* A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome. *Nature Communications* **7**, 10900, doi:10.1038/ncomms10900 (2016).
- 8 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of *Coot. Acta Crystallographica Section D Biological Crystallography* **66**, 486-501, doi:10.1107/s0907444910007493 (2010).
- 9 Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res* **32**, 1792-1797, doi:10.1093/nar/gkh340 (2004).
- 10 Capella-Gutierrez, S., Silla-Martinez, J. M. & Gabaldon, T. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* **25**, 1972-1973, doi:10.1093/bioinformatics/btp348 (2009).

- 11 Jones, D. T., Taylor, W. R. & Thornton, J. M. The rapid generation of mutation data matrices from protein sequences. *Comput Appl Biosci* **8**, 275-282, doi:10.1093/bioinformatics/8.3.275 (1992).
- 12 Maddison, W. & Maddison, D. R. Mesquite: A modular system for evolutionary analysis. *Evolution* **62**, 1103-1108 (2008).
- 13 Revell, L. J. phytools: an R package for phylogenetic comparative biology (and other things). *Methods in Ecology and Evolution* **3**, 217-223, doi:10.1111/j.2041-210X.2011.00169.x (2012).
- 14 Durfee, T. *et al.* The Complete Genome Sequence of *Escherichia coli* DH10B: Insights into the Biology of a Laboratory Workhorse. *Journal of Bacteriology* **190**, 2597-2606, doi:10.1128/jb.01695-07 (2008).
- 15 Schimming, O., Fleischhacker, F., Nollmann, F. I. & Bode, H. B. Yeast Homologous Recombination Cloning Leading to the Novel Peptides Ambactin and Xenolindicin. *ChemBioChem* **15**, 1290-1294, doi:10.1002/cbic.201402065 (2014).
- 16 Goldman, B. S. *et al.* Evolution of sensory complexity recorded in a myxobacterial genome. *Proceedings of the National Academy of Sciences* **103**, 15200-15205, doi:10.1073/pnas.0607335103 (2006).
- 17 Krug, D. *et al.* Discovering the hidden secondary metabolome of Myxococcus xanthus: a study of intraspecific diversity. *Appl Environ Microbiol* **74**, 3058-3068, doi:10.1128/AEM.02863-07 (2008).
- 18 Kissoyan, K. A. B. *et al.* Natural C. elegans Microbiota Protects against Infection via Production of a Cyclic Lipopeptide of the Viscosin Group. *Current Biology* 29, 1030-1037.e1035, doi:10.1016/j.cub.2019.01.050 (2019).
- 19 Petersen, L. M. & Tisa, L. S. Influence of temperature on the physiology and virulence of the insect pathogen Serratia sp. Strain SCBI. *Appl Environ Microbiol* **78**, 8840-8844, doi:10.1128/AEM.02580-12 (2012).
- 20 Joyce, S. A. & Clarke, D. J. A hexA homologue from Photorhabdus regulates pathogenicity, symbiosis and phenotypic variation. *Molecular Microbiology* **47**, 1445-1457, doi:10.1046/j.1365-2958.2003.03389.x (2003).
- 21 Tobias, N. J. *et al.* Natural product diversity associated with the nematode symbionts Photorhabdus and Xenorhabdus. *Nature Microbiology* **2**, 1676-1685, doi:10.1038/s41564-017-0039-9 (2017).
- 22 Behsaz, B. *et al.* Integrating genomics and metabolomics for scalable non-ribosomal peptide discovery. *Nature Communications* **12**, doi:10.1038/s41467-021-23502-4 (2021).
- 23 Lorenzen, W., Ahrendt, T., Bozhüyük, K. A. J. & Bode, H. B. A multifunctional enzyme is involved in bacterial ether lipid biosynthesis. *Nature Chemical Biology* **10**, 425-427, doi:10.1038/nchembio.1526 (2014).
- 24 Kegler, C. & Bode, H. B. Artificial Splitting of a Non-Ribosomal Peptide Synthetase by Inserting Natural Docking Domains. *Angewandte Chemie* **132**, 13565-13569, doi:10.1002/ange.201915989 (2020).
- 25 Fuchs, S. W., Proschak, A., Jaskolla, T. W., Karas, M. & Bode, H. B. Structure elucidation and biosynthesis of lysine-rich cyclic peptides in Xenorhabdus nematophila. *Organic & Biomolecular Chemistry* **9**, 3130, doi:10.1039/c1ob05097d (2011).
- 26 Vo, T. D., Spahn, C., Heilemann, M. & Bode, H. B. Microbial Cationic Peptides as a Natural Defense Mechanism against Insect Antimicrobial Peptides. *ACS Chemical Biology* **16**, 447-451, doi:10.1021/acschembio.0c00794 (2021).
- 27 Sievers, F. & Higgins, D. G. Clustal Omega for making accurate alignments of many protein sequences. *Protein Sci* **27**, 135-145, doi:10.1002/pro.3290 (2018).
- 28 Blin, K. *et al.* antiSMASH 6.0: improving cluster detection and comparison capabilities. *Nucleic Acids Res* **49**, W29-W35, doi:10.1093/nar/gkab335 (2021).
- 29 Niehs, S. P. *et al.* Genome Mining Reveals Endopyrroles from a Nonribosomal Peptide Assembly Line Triggered in Fungal–Bacterial Symbiosis. ACS Chemical Biology 14, 1811-1818, doi:10.1021/acschembio.9b00406 (2019).
- 30 Wang, X. *et al.* Discovery of recombinases enables genome mining of cryptic biosynthetic gene clusters in Burkholderiales species. *Proc Natl Acad Sci U S A* **115**, E4255-E4263, doi:10.1073/pnas.1720941115 (2018).
- 31 Isogai, A. *et al.* Structural Analysis of New Syringopeptins by Tandem Mass Spectrometry. *Bioscience, Biotechnology, and Biochemistry* **59**, 1374-1376, doi:10.1271/bbb.59.1374 (1995).